行情

MGNX

MGNX

MacroGenics
NASDAQ

实时行情|Nasdaq Last Sale

12.96
-0.17
-1.29%
交易中 10:09 09/18 EDT
开盘
13.12
昨收
13.13
最高
13.20
最低
12.87
成交量
3.34万
成交额
--
52周最高
32.32
52周最低
9.87
市值
6.34亿
市盈率(TTM)
-3.7049
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MGNX 新闻

  • IMF首席经济学家:全球经济前景受限 需要财政支持
  • 新浪美股.4分钟前
  • 美国总统特朗普宣布加大对伊朗制裁
  • 央视.21分钟前
  • 下调全年盈利指引 联邦快递大跌逾12%
  • 智通财经网.29分钟前
  • 开盘:等待联储决议 美股周三低开
  • 新浪美股.39分钟前

更多

所属板块

生物技术和医学研究
-0.73%
制药与医学研究
-0.23%

热门股票

名称
价格
涨跌幅

MGNX 简况

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
展开

Webull提供MacroGenics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。